T1	Participants 157 192	advanced colorectal cancer patients
T2	Participants 615 694	advanced colorectal cancer (ACC) patients treated in the phase III CAIRO2 study
T3	Participants 718 796	Seven hundred and fifty five previously untreated ACC patients were randomised
T4	Participants 1116 1186	Seven hundred and thirty two patients were evaluable for this analysis
T5	Participants 1188 1278	The Ca/Mg(+) group consisted of 551 patients, the Ca/Mg(-) group consisted of 181 patients
T6	Participants 961 1106	two groups: patients in the Ca/Mg(+) group received Ca/Mg at least during their first treatment cycle, and patients in the Ca/Mg(-) group did not
